| Income statement (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | 20.07B | 16.75B | 14.24B | 12.68B | 11.89B | 9.91B |
| Cost of revenue | 6.22B | 5.26B | 4.34B | 3.96B | 3.71B | 3.46B |
| Gross profit | 13.85B | 11.49B | 9.90B | 8.73B | 8.18B | 6.45B |
| Research and development | 2.05B | 1.61B | 1.41B | 1.32B | 1.20B | 1.14B |
| Selling, general and admin | 6.89B | 5.98B | 5.19B | 4.52B | 4.36B | 3.79B |
| Operating expenses | 10.24B | 8.89B | 7.55B | 7.08B | 6.98B | 6.53B |
| Operating income | 3.61B | 2.60B | 2.34B | 1.65B | 1.20B | -80.00M |
| EBITDA | 4.98B | 3.87B | 3.54B | 2.79B | 2.29B | 1.04B |
| Interest expense | 349.00M | 305.00M | 265.00M | 470.00M | 341.00M | 361.00M |
| Income before tax | 3.38B | 2.28B | 1.99B | 1.14B | 1.08B | -79.00M |
| Income tax | 493.00M | 436.00M | 393.00M | 443.00M | 36.00M | 2.00M |
| Net income | 2.90B | 1.85B | 1.57B | 642.00M | 985.00M | -115.00M |
| EPS | 1.96 | 1.26 | 1.08 | 0.45 | 0.69 | -0.08 |
| EPS (diluted) | 1.94 | 1.25 | 1.07 | 0.45 | 0.69 | -0.08 |
| Diluted shares | 1.49B | 1.49B | 1.46B | 1.44B | 1.43B | 1.42B |
From Boston Scientific's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.